Vensana Capital Closes $425M MedTech Investment Fund Oversubscribed

Vensana Capital has successfully closed its latest fund, Vensana Capital III, with $425 million in committed capital. The firm, founded in 2019, focuses on partnering with innovative medical technology companies in their development and commercial stages. With the oversubscribed fund, Vensana's total capital under management is now approximately $1 billion.

The investment firm has a strong track record, having partnered with over 20 companies and achieving six exits totaling nearly $3 billion in value. The firm's portfolio includes companies advancing first-in-class and best-in-class products in various areas of medtech. Vensana's team, led by Managing Partners Kirk Nielsen and Justin Klein, MD, JD, is excited about the future and continues to seek opportunities to partner with entrepreneurs driving breakthrough innovations in medical technology.

The firm's investment team is further strengthened by an advisory board comprised of medtech entrepreneurs, senior executives, and subject matter experts. Vensana Capital's focus areas include medical devices, data science-oriented solutions, life science tools & diagnostics, and tech-enabled services.

Source: Business Wire